Cancer-promoting inflammation is an important event in cancer development.
Introduction
Inflammation occurring in cancer tissues promotes cancer progression by providing various factors, such as growth factors, pro-angiogenic factors, enzymes required for cancer invasion and metastasis, and immune-suppressive factors. Thus, such inflammation is called cancer-promoting inflammation 1, 2 . Being recognised as one of the hallmarks of cancer, cancer-promoting inflammation is a promising target for cancer therapy 1 . Among various processes causing cancer-promoting inflammation, the pathway of cyclooxygenase 2 (COX2) and its metabolite prostaglandin E2 (PGE2) has been widely accepted as important in human cancers 2 . COXs are rate-limiting enzymes required for the biosynthesis of PGs in the arachidonic acid cascade, and PGE2 is the most abundant COX metabolite. Under physiological conditions, COX2 and PGE2 are induced during inflammatory processes and act as pro-inflammatory factors 3 . COX2 overexpression and subsequent PGE2 overproduction are observed in various human cancers [4] [5] [6] [7] and play a crucial role in the development of the tumour-promoting inflammatory microenvironment 2, 8 .
Canine urothelial carcinoma (cUC) is the most common malignancy affecting the lower urinary tract of dogs. cUC is a unique tumour often well managed using COX inhibitors or non-steroidal anti-inflammatory drugs (NSAIDs) 9 . In addition, COX2 is overexpressed in cUC [10] [11] [12] . We previously reported that cUC cell lines overexpress PGE2 in vitro compared to other canine tumour cell lines with different tissues of origin 13 .
Further, we suggested that aberrant PGE2 production is important for development of the tumour microenvironment and not for cell proliferation or survival 13 . However, the pathway that induces upregulation of COX2/PGE2 axis in cUC cells was not elucidated.
Another characteristic of cUC is that a single nucleotide mutation in the BRAF gene, V595E, is detected in 70%-80% of canine patients 14, 15 . BRAF is an isoform of RAF serine/threonine kinase, which belongs to the RAF/MEK/ERK pathway. This pathway is one of the most important signalling pathways that transmit extracellular signals to cell nuclei, thereby regulating cell proliferation, differentiation, survival, and various other cellular functions. The canine homologous mutation BRAF V595E , which is recognized as BRAF V600E , is frequently observed in a variety of human malignancies such as malignant melanoma, colorectal cancer, and papillary thyroid cancer [16] [17] [18] . The BRAF V600E mutation reportedly induces oncogenic cellular proliferation via constitutive activation of the RAF/MEK/ERK pathway 16, 19 . Therefore, several molecular targeting drugs against BRAF V600E have been established and have improved the prognosis of patients with cancer 20, 21 . Although canine BRAF V595E is also suggested to contribute to constitutive activation of the RAF/MEK/ERK signalling cascade, its importance in cUC Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 4 progression remains unclear.
In this study, we screened molecular targeting agents to determine the pathways involved in PGE2 production in BRAF mutant cUC cells. Subsequently, we investigated the contribution of the RAF/MEK/ERK pathway in the regulation of the COX2/PGE2 axis in BRAF mutant cUC cells. We also analysed the association between COX2 expression and the BRAF genotype in cUC tissues. Our findings indicate a novel association between oncogenic activation of the RAF/MEK/ERK pathway in BRAF mutant cUC cells and dysregulation of the COX2/PGE2 axis.
Results
In vitro drug screening for disruption of PGE2 production in BRAF mutant cUC cells We previously reported that cUC cell lines overexpress PGE2 13 . To elucidate the mechanisms underlying aberrant PGE2 production in cUC cells, we screened 332 inhibitor compounds using SCADS inhibitor kit 1-4 obtained from Molecular Profiling Committee, Grant-in-Aid for Scientific Research on Innovative Areas "Advanced Animal Model Support (AdAMS)" from The Ministry of Education, Culture, Sports, Science and Technology, Japan (KAKENHI 16H06276; see Supplementary Table S1 ). A BRAF mutant cUC cell line, Sora, was treated with each inhibitor compound at 10 µM for 12 h. The amount of PGE2 in the medium was quantified after the treatment, and percent change in PGE2 production with respect to that in vehicle control (DMSO) was calculated ( Fig. 1A and see Supplementary Table S1 ). Eighty compounds showed ≥50% reduction in PGE2 production in cUC cells. After categorization of all the compounds into their specific target biological pathways, enrichment of each category for the PGE2-suppressing compounds was analysed. Statistical analysis revealed that compounds targeting the arachidonic acid cascade (FDR = 0.086), RAF/MEK/ERK pathway (FDR = 0.067), and p38/JNK pathway (FDR = 0.067) were enriched in these 80 compounds (Table 1 and Fig. 1A and 1B ). In addition, the compounds against the enriched pathways did not show strong cytotoxic effects on BRAF mutant cUC cells ( Fig.   1B ). Since the arachidonic acid cascade falls directly upstream of PGE2 production, we focused on the RAF/MEK/ERK and p38/JNK pathways as potential biological activators of the COX2/PGE2 axis in cUC cells.
Effects of MAPK inhibition on expression of the COX2/PGE2 axis
To evaluate whether the RAF/MEK/ERK and p38/JNK pathways are involved in PGE2 production in BRAF mutant cUC cells, Sora cells were treated with the following compounds that specifically inhibit components of various pathways: dabrafenib (BRAF inhibitor), LY3009120 (pan-RAF inhibitor), PD0325901 (MEK inhibitor), SCH772984 (ERK inhibitor), SB239063 (p38 inhibitor), and SP600125 (JNK inhibitor). All Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 5 compounds were used at 1 µM for 0, 6, 12, and 24 h. After 6 h of treatment, we noted that COX2 expression and PGE2 production were decreased by RAF/MEK/ERK inhibitors ( Fig. 2A ). In the case of the p38/JNK pathway, although p38 inhibition led to the suppression of COX2 expression and PGE2 production, JNK inhibition increased the expression of COX2 despite decreased PGE2 production (see Supplementary Fig. S1A,   B ). Further, the cells were exposed to each compound at varying concentrations for 12 h.
In this case too, RAF/MEK/ERK inhibitors suppressed COX2 expression and PGE2 production in cUC cells in a dose-dependent manner ( Fig. 2B and see Supplementary   Fig . S1B). Finally, six BRAF mutant cUC cell lines (TCCUB, Love, Nene, NMTCC, LTCC, and MCTCC) and one BRAF wild type cUC cell line (OMTCC) were treated with the inhibitors with the varying doses for 12 h. In five of the seven cell lines, which showed comparatively higher PGE2 production when cultured in the basal medium (see Supplementary Fig. S2 ), decreases in COX2 expression and PGE2 production were observed when the RAF/MEK/ERK pathway was inhibited ( Fig. 2C ). On the contrary, OMTCC and MCTCC, which show mild expression of the COX2/PGE2 axis among the seven cUC cell lines, did not show change in COX2/PGE2 expression ( Fig. 2C ).
Association between BRAF mutation and COX2 expression
To further examine the association between the COX2/PGE2 axis and the RAF/MEK/ERK pathway in patients with cUC, we performed immunohistochemical analysis of COX2 expression and genotyping of the BRAF gene. The levels of COX2 expression were analysed using a semi-quantitative method described in previous reports ( Fig. 3a) 10, 22, 23 . Digital PCR-based BRAF genotyping identified BRAF mutation in 33 cUC tissues, while 10 tumours were BRAF wild-type. cUC tissues with BRAF mutation tended to express higher levels of COX2, although the difference between mutant tumours and wild-type tumours was not significant (p = 0.0569; Fig. 3b and 3c)
Discussion
The COX2/PGE2 axis plays a crucial role in tumour development. In several human tumours, it has been revealed that the COX2/PGE2 axis is affected by oncogenic mutations 24, 25 . A few recent reports suggested that BRAF V600E , one of the most common driver mutations in human cancer, contributed to COX2/PGE2 overexpression 26 . Our results of drug screening indicated that among various biological signalling pathways, the RAF/MEK/ERK pathway facilitates PGE2 production in cUC cells. We further showed that oncogenic activation of the RAF/MEK/ERK pathway may lead to aberrant upregulation of the COX2/PGE2 axis in BRAF mutant cUC cells. We also suggested that the BRAF genotype in cUC tissues may predict overexpression of COX2. From these Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 6 observations, we concluded that highly penetrated BRAF mutation in cUC cells probably contributes to activation of the RAF/MEK/ERK pathway and subsequent induction of the COX2/PGE2 axis to prepare the pro-tumoral microenvironment. This, in turn, may confer notable COX inhibitor vulnerability to the tumour, as widely observed in veterinary clinical practice.
Recent studies have reported that activation of the RAF/MEK/ERK pathway promotes COX2 expression and PGE2 production in human cancers. A couple of studies suggested that ERK signalling activated by hepatocyte growth factor leads to increased COX2 expression in human colorectal cancer and non-small cell lung cancer 27, 28 .
Further, a recent study that investigated BRAF mutant melanoma cells established from genetically engineered mice suggested that COX2/PGE2 expression depends on RAF/MEK/ERK pathway activation 26 . In this study, we suggested that the activation of the RAF/MEK/ERK pathway is involved in the overexpression of the COX2/PGE2 axis in BRAF mutant cUC cells. Thus, our findings indicate close analogy of biological mechanisms of carcinogenesis or tumour progression between humans and dogs.
cUC is a unique tumour often managed with NSAID monotherapy, indicating the importance of the COX2/PGE2 axis in the development and progression of cUC 9 .
Since no direct cytotoxicity was observed in our previous study 13 , the therapeutic effect of NSAIDs was considered to be exerted via blocking the effect of eicosanoids, specifically PGE2, on tumour microenvironment. This hypothesis was further supported in this study by the fact that no correlation was observed between suppression of PGE2 production and cell growth. Therefore, the findings of this study suggest that BRAF In this study, the BRAF inhibitor dabrafenib showed weaker inhibitory effect on ERK phosphorylation and COX2/PGE2 expression than other inhibitors. In addition, during drug screening, all inhibitors targeting the RAF/MEK/ERK pathway did not show strong inhibition of cUC cell growth even at high concentration. Several kinds of human cancers also show similar primary resistance with ERK reactivation to BRAF inhibitors [29] [30] [31] . These instances of primary resistance are attributed to "paradoxical activation" of ERK signalling through other RAF isoforms or RAF dimers 30, 32, 33 . The resistance of cUC tot BRAF inhibitors observed in this study may have the same underlying mechanisms, since MEK or pan-RAF inhibitors were able to suppress ERK Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 7 phosphorylation for a long period.
PGE2, one of the products of COX2, has been reported to be an inducer of cancer-promoting inflammation 2 . On the contrary, in the arachidonic acid cascade, there are some tumour suppressors such as PGD2 34, 35 . In our previous study, BRAF mutant cUC cells also produced large amounts of PGD2 compared to other cells 13 . Although in the current study, we focused on PGE2 as it is a major product of COX2, PGD2 or other tumour-suppressing factors could be regulated by the activation of the RAF/MEK/ERK pathway in BRAF mutant cUC cells. The regulation of other products and the overall effect of RAF/MEK/ERK inhibition on tumour microenvironment should be further investigated.
In vitro drug screening revealed the candidate mechanisms for increased production of PGE2 in cUC cells. Although we focused on the RAF/MEK/ERK pathway in this study, the stress-activated protein kinases p38 and JNK were also suggested to be important for PGE2 overproduction in initial screening. p38 and JNK are members of the MAPK family and activated by environmental stress, including ultraviolet exposure, oxidative stress, or inflammatory cytokines 36 . They have been suggested to induce COX2 expression in inflammatory processes, such as rheumatoid arthritis or Parkinson's disease, and in human cancer-promoting inflammation [37] [38] [39] . Our results suggested that the p38/JNK pathway also regulates PGE2 production in cUC cells in a manner different from that of the RAF/MEK/ERK pathway. Therefore, the mechanisms underlying the activation of the p38/JNK pathway and its role in cUC progression requires further investigation.
In the histological analysis, BRAF mutant cUC cells tended to show higher expression of COX2. In a recent study, the association between BRAF mutation and COX2 expression was only observed in cUC tissues of specific dog breeds 40 . Further, in our in vitro study, one of the BRAF mutant cUC cell lines did not overexpress COX2 and
PGE2. Notably, this cell line did not show ERK reactivation upon BRAF inhibition,
indicating that BRAF mutation does not necessarily cause RAF/MEK/ERK pathway activation in the same manner. Another possibility is that the RAF/MEK/ERK pathway is activated by different mutations in BRAF wildtype tumours. Further study about dysregulation of the RAF/MEK/ERK pathway as well as variability in the consequences of BRAF mutations will lead to further understanding of cUC pathogenesis.
In conclusion, our study revealed that overexpression of the COX2/PGE2 axis in cUC cells harbouring the BRAF mutation is related to the activation of the RAF/MEK/ERK pathway. The importance of COX2/PGE2 expression and BRAF mutation has been highlighted in several human cancers. Therefore, our findings can be Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 8 extrapolated to human medicine as well. In the future, validation through "gain of function" studies using genetic engineering techniques accompanied by in vivo studies is required. Moreover, a greater patient sample size for immunohistochemical analysis would be beneficial.
cUC is a unique tumour that shows notable response to COX inhibitors. We believe that cUC can be an excellent model to study the relationship between oncogenic instructions. To normalize the amount of PGE2 to the cell density, direct cell count or 20 sulforhodamine B (SRB) assay was performed 43 . 21 In vitro drug screening 22 Sora cells were seeded in a 96-well plate at a density of 11,000 cells per well. After 24-h 23 incubation, the culture medium in each well was discarded, and fresh medium 24 containing the drugs from the SCADS inhibitor kits was added at a final concentration 25 of 10 µM. After 12-h incubation, the culture supernatants were collected. After 26 normalizing PGE2 production to cell density as mentioned above, percentage change in 27 PGE2 production from control was calculated. 28 Growth inhibition 29 To compare with the changes in PGE2 production, data regarding cell growth inhibition 30 after treatment with the inhibitors from the SCADS inhibitor kits were obtained from 31 our previous study. Detailed protocol is described in our previous study 24 . Briefly, Sora 32 cells were treated with the drugs from the SCADS inhibitor kits at 10 µM as described 33 in In vitro drug screening section. After 72-h incubation, cell densities were determined 34 by SRB assay. 35 Protein detection cUC cells were seeded in serum-free medium and incubated for 24 h as in our previous 37 report (see Supplementary Table S2) 24 . After 24-h serum starvation, cUC cells were 38 treated with final concentration of 10% FBS and RAF/MEK/ERK inhibitors as indicated 39 in each figure. After treatment for the indicated times, cells were lysed for 30 min on ice 40 in RIPA buffer consisting of 50 mM Tris-HCl, 150 mM NaCl, 5 mM EDTA, 0.1% sodium 41 dodecyl sulphate, 1% Triton-X, 10 mM NaF, 2 mM NaVO4, and complete protease 42 inhibitor cocktail (Roche Diagnostics). After centrifugation, protein concentrations were 43 measured using bicinchoninic acid protein assay kit. Equal amounts (10 µg) of total 44 protein were separated by sodium dodecyl sulphate-polyacrylamide gel electrophoresis 45 and transferred to polyvinylidene difluoride membranes. The membranes were blocked 46 with 5 % skim milk in Tris-buffered saline containing 0.1% Tween (TBST) for 1 h at 47 room temperature to avoid non-specific antibody binding. Further, the membranes were 48 incubated overnight at 4° C with each primary antibody (see Supplementary Table S3 ). 49
The membranes were then washed with TBST and incubated with horseradish 50 peroxidase-conjugated anti-mouse or anti-rabbit secondary antibody (1:10000) from GE 51
Healthcare for 1 h at room temperature. Protein signal was developed with a 52 chemiluminescent system (Merck Millipore) and captured with an imaging system 53 respective hospitals provided informed consent for the use of these samples for this 61 study. cUC tissues of 4 μm thickness were deparaffinized in xylene and hydrated in 62 graded alcohol. Antigen retrieval was performed for 10 min at 121° C in citrate buffer 63 (pH 6.0). The sections were then treated with 3% hydrogen peroxide for 30 min at room 64 temperature. After blocking with 5% normal goat serum in TBST for 1 h at room 65 temperature, the sections were incubated overnight with 1:100 of anti-COX2 mouse 66 monoclonal antibody (BD Bioscience) at 4° C in a humidified chamber. Subsequently, 67 the sections were rinsed with TBST and then incubated with EnVision polymer reagent 68 for mouse (Dako) for 60 min at room temperature. After rinsing with TBST again, 69 peroxidase reactions were developed for 3 min with 3,3′-diaminobenzidine (Dako). The 70 sections were counterstained with haematoxylin. 71 BRAF genotyping 72 Yoshitake et al, Sep 28, 2019 -preprint version -www.biorxiv.org 11 BRAF genotype of cUC tissue was determined as described in a previous study 42 Immunohistochemical evaluation 78 For scoring COX2 expression in cUC tissue, a semi-quantitative immunohistochemical 79 score (IHS) system described in a previous report was used 10, 22, 23 . Briefly, the percentage 80 of COX2-positive tumour cells in the entire section and their signal intensity were 81 evaluated when viewed at 100x and 200x magnification, respectively. Positivity was 82 graded as 1 = <1%, 2 = 1%-9%, 3 = 10%-50%, 4 = >50%, and intensity was graded as 0 = 83 no staining, 1 = mild staining, 2 = moderate staining, 3 = strong staining. IHS was 84 obtained by multiplying positivity score and intensity score. 42 . Drugs which showed ≥50% reduction in PGE2 production and ≥80% reduction in cell viability were included in statistical analysis. Categories which have more than 3 inhibitors are presented in this graph. Node size represents proportion of the drugs which showed reduction more than the threshold in each category. Colour represents statistical significance. 
